Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...

The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...

Regulatory reviews for ribociclib among patients with early breast cancer are continuously ongoing to include the EMA and China. 1. FDA approves Kisqali with an aromatase inhibitor and Kisqali Femara ...

Ribociclib 200mg; with letrozole 2.5mg; tabs. Ribociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. These kinases are activated upon binding to D-cyclins and play a crucial role in ...

Whakatāne sisters Nicki Hagen (left) and Rochelle Hollowood were diagnosed with breast cancer two years apart. Photo supplied ...

Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...

Stretching PFS in ER-Positive Metastatic Breast Cancer In metastatic breast cancer, the current 14-16 months of PFS with endocrine therapy can be stretched to more than 20 months in the first-line ...

Findings from the NATALEE trial show that the combination of Kisqali and an aromatase inhibitor resulted in disease-free ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment ...